Mainz Biomed (NASDAQ:QUCY) Upgraded by Zacks Research to Hold Rating

Mainz Biomed (NASDAQ:QUCY) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities research analysts have also recently commented on QUCY. Wall Street Zen upgraded shares of Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. Litchfield Hills Research upgraded shares of Mainz Biomed to a “strong-buy” rating in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mainz Biomed in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Mainz Biomed Stock Down 4.7%

QUCY opened at $1.30 on Tuesday. Mainz Biomed has a one year low of $0.30 and a one year high of $4.93. The stock has a fifty day moving average price of $1.48. The company has a market cap of $19.13 million, a P/E ratio of -0.03 and a beta of 2.31.

Trending Headlines about Mainz Biomed

Here are the key news stories impacting Mainz Biomed this week:

• Positive Sentiment: Litchfield Hills Research upgraded Mainz Biomed to “Strong-Buy,” providing a favorable analyst signal for the small-cap biotechnology stock. Mainz Biomed Upgraded at Litchfield Hills Research
• Positive Sentiment: Litchfield Hills forecasts improving earnings trends, with projected losses narrowing from $1.12 per share for fiscal 2026 to $0.55 in fiscal 2027 and $0.07 in fiscal 2028. The estimates suggest analysts expect progress toward breakeven, though they do not yet forecast profitability. Mainz Biomed analyst earnings estimates
• Neutral Sentiment: The analyst’s near-term estimates remain negative, including expected losses of $0.63 per share in the second quarter of 2026 and $1.12 per share for the full year, highlighting continued cash-burn and execution risk.
• Neutral Sentiment: Reported short interest was zero shares, indicating no meaningful short-selling activity in the data provided. This removes a potential source of short-covering demand but also offers little additional trading signal.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.